Related Experiment Video
Updated: Sep 11, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and
Mohammad Hamza1, Mubashar Karamat2, Khaled M Harmouch3
1Department of Internal Medicine, Guthrie Medical Group, New York, NY, USA.
Background:
Clopidogrel non-responder is a common dilemma in the management of post-percutaneous coronary intervention (PCI) management. Clopidogrel is metabolized by CYP2C19. The genetic variations in CYP2C19 can affect the efficacy and bioavailability of the drug that can be checked via genotype testing of the gene. This study evaluates the impact of genotype versus conventional guided P2Y12 inhibitor therapy on post-PCI patient outcomes.
Methods:
Guided by PRISMA and AMSTAR-2, we analyzed 10 trials comparing genotype-guided and conventional P2Y12 inhibitor therapy in post-PCI patients. Our search, spanning up to October 2022 across major databases, focused on adult populations undergoing PCI, assessing outcomes like mortality, MACE, myocardial infarction, stroke, stent thrombosis, and bleeding events.
Results:
A total of 10 studies involving 4300 patients were selected in pooled analysis, genotype-guided therapy markedly reduced all-cause mortality (RR: 0.59; 95% CI: 0.37-0.95) and MACE (RR: 0.66; 95% CI: 0.49-0.88), without a significant increase in bleeding events (RR: 0.83; 95% CI: 0.61-1.14). Furthermore, significant reductions were observed in myocardial infarction (RR: 0.59; 95% CI: 0.44-0.78) and stent thrombosis (RR: 0.55; 95% CI: 0.3-0.996), with stroke also seeing a decrease (RR: 0.56; 95% CI: 0.35-0.9).
Conclusion:
Genotype-guided P2Y12 inhibitor therapy significantly improves outcomes for post-PCI patients, reducing mortality, MACE, myocardial infarction, and stent thrombosis without increasing bleeding risk. These findings support the integration of genetic testing into clinical decision-making for DAPT optimization.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care

